Tumor promoting function of β-catenin has been repeatedly validated: oncogenic mutations in CTNNB1 frequently found in HCC patients; therapeutic effect in preclinical tumor models has been reported with drug targeting β-catenin. This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.